Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423860 · ClinicalTrials.gov registry record
Phase I Human Analytics (HALO) Study
A clinical trial of Cancer and Cardiovascular Diseases, sponsored by HALO Diagnostics.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 1
- Study location
NCT05423860: Recruiting study of Cancer and Cardiovascular Diseases, sponsored by HALO Diagnostics.
NCT05423860 is a study of Cancer and Cardiovascular Diseases that is actively recruiting participants, run by HALO Diagnostics. The registered enrollment target is 2,000 participants, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423860, a study of Cancer and Cardiovascular Diseases, is actively recruiting participants, sponsored by HALO Diagnostics.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinical states, in preclinical states, and to develop ensemble multivariate biomarker risk scores leading to cardiovascular, oncologic, neurologic, and other diseases and disorders. Additionally, the study aims to: * Evaluate data analysis techniques to improve diagnostic accuracy and reduce time to diagnosis. * Evaluate data analysis techniques to improve risk stratification for participants through machine learning algorithms. * Direct participants to relevant and applicable clinical trials.
Primary Outcome
Measure a patient's prostate cancer Gleason score for patients with a prostate cancer diagnosis and record the measurement again at 3, 6, 9 months and annually for 5 years after treatment. We will use the pathology report submitted by the pathologist. The Gleason Score ranges from 1-5 and describes how much the cancer from a biopsy looks like healthy tissue (lower score) or abnormal tissue (higher score).
Conditions Studied
Interventions
- OTHER no interventions will be performed (observational)
Study Locations (1)
California
- Desert Medical Imaging - Indian Wells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2022-03-16 |
| Est. Completion | 2037-03 |
What NCT05423860 shows while recruiting
NCT05423860 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus, below the 3,488-participant average among 615 other Cancer trials with a reported enrollment target (43% lower).
The record links to 4 conditions, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which no interventions will be performed (observational) is the first listed.
NCT05423860 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05423860 about?
NCT05423860 is a clinical study titled "Phase I Human Analytics (HALO) Study". Discover, optimize, standardize, and validate clinical-trial measures and biomarkers used to diagnose and differentiate cardiovascular, oncologic, neurologic, and other diseases and disorders. Specifically, our research study endeavors to improve disease and disorder diagnosis to the earliest clinic...
What is the current status of trial NCT05423860?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2022-03-16. Estimated completion is 2037-03.
What conditions does trial NCT05423860 study?
This clinical trial studies the following conditions: Cancer, Cardiovascular Diseases, Dementia, Traumatic Brain Injury.
What interventions are being tested in trial NCT05423860?
The interventions under investigation include: no interventions will be performed (observational) (OTHER).
Who is sponsoring clinical trial NCT05423860?
This trial is sponsored by HALO Diagnostics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05423860 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05423860's enrollment target sits among peer trials
2,000 56th of 615 higher than 553 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI